Maxwell Meng, MD

Urologic cancer surgeon

Dr. Maxwell Meng is a surgeon specializing in urologic cancers and laparoscopy. His clinical interests include the diagnosis and management of genitourinary malignancy and minimally invasive treatment of benign and malignant diseases. Meng, actively involved in developing new treatment technologies, is also experienced in robotic surgery.

Meng earned a medical degree at Johns Hopkins School of Medicine and completed general surgery and urology training at UCSF, where he also completed fellowships in urologic oncology and minimally invasive surgery. He is a professor in the UCSF Department of Urology.


Prostate Cancer Center
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Medical Oncology Phone: (415) 476-4616
Surgical Oncology Phone: (415) 353-7171
Medical Oncology Fax: (415) 353-7107
Surgical Oncology Fax: (415) 514-6195

Hours: Monday to Friday
8 a.m. – 5 p.m.

Urologic Surgical Oncology Clinic
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Phone: (415) 353-7171
New Patient Fax: (415) 514-6195
General Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

Board Certification

Urology, American Board of Urology

Academic Title


More about Maxwell Meng


John Hopkins University 1995


UCSF Urology Dept., Urology 2001


UCSF Urology Dept., Urology 2002

Selected Research and Publications

  1. Sanford T, Meng MV, Railkar R, Agarwal PK, Porten SP. Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma. Clin Epigenetics. 2018; 10:19.
  2. Welty CJ, Sanford TH, Wright JL, Carroll PR, Cooperberg MR, Meng MV, Porten SP. The Cancer of the Bladder Risk Assessment (COBRA) score: Estimating mortality after radical cystectomy. Cancer. 2017 Dec 01; 123(23):4574-4582.
  3. Garcia MM, Gottschalk AR, Brajtbord J, Konety BR, Meng MV, Roach M, Carroll PR. Correction: Endoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial Outcomes. PLoS One. 2016; 11(10):e0164558.
  4. Nguyen HG, Punnen S, Cowan JE, Leapman M, Cary C, Welty C, Weinberg V, Cooperberg MR, Meng MV, Greene KL, Garcia M, Carroll PR. A Randomized Study of Intraoperative Autologous Retropubic Urethral Sling on Urinary Control after Robotic Assisted Radical Prostatectomy. J Urol. 2017 Feb; 197(2):369-375.
  5. Leapman MS, Ameli N, Shinohara K, Nguyen HG, Meng MV, Cooperberg MR, Carroll PR. Validity of the Cancer of the Prostate Risk Assessment Score Derived From Targeted Biopsy: Modeling Evidence From Ultrasound Lesion-Directed Biopsy. Clin Genitourin Cancer. 2017 Feb; 15(1):93-99.
  6. Leapman MS, Clark CJ, Meng MV, Boughey JC. Diet and lifestyle can influence prostate cancer outcomes. Bull Am Coll Surg. 2016 07; 101(7):50-2.
  7. Meng MV. Editorial Comment. Urology. 2016 05; 91:232-3.
  8. Odisho AY, Rabban JT, Meng MV. Development of CNS-type Primitive Neuroectodermal Tumor in Metastatic Testicular Mixed Germ Cell Tumor. Urol Case Rep. 2016 May; 6:7-8.
  9. Yang X, Zhang K, Ye X, Zheng A, Huang G, Li W, Wei Z, Wang J, Han X, Ni X, Meng M, Ni Y, Yuan Q, Xing C. Artificial pneumothorax for pain relief during microwave ablation of subpleural lung tumors. Indian J Cancer. 2015 Dec; 52 Suppl 2:e80-3.
  10. Li W, Ye X, Yang X, Li Y, Huang G, Wang J, Han X, Ni X, Wei Z, Zheng A, Meng M. Microwave ablation as palliative treatment of locally recurrent colorectal cancer. Indian J Cancer. 2015 Dec; 52 Suppl 2:e61-3.
  11. Tang Q, Song Y, Li X, Meng M, Zhang Q, Wang J, He Z, Zhou L. Prognostic Outcomes and Risk Factors for Patients with Renal Cell Carcinoma and Venous Tumor Thrombus after Radical Nephrectomy and Thrombectomy: The Prognostic Significance of Venous Tumor Thrombus Level. Biomed Res Int. 2015; 2015:163423.
  12. Newcomb LF, Thompson IM, Boyer HD, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Ellis WJ, Fazli L, Feng Z, Gleave ME, Kunju P, Lance RS, McKenney JK, Meng MV, Nicolas MM, Sanda MG, Simko J, So A, Tretiakova MS, Troyer DA, True LD, Vakar-Lopez F, Virgin J, Wagner AA, Wei JT, Zheng Y, Nelson PS, Lin DW. Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. J Urol. 2016 Feb; 195(2):313-20.
  13. Sanford T, Porten S, Meng MV. Molecular Analysis of Upper Tract and Bladder Urothelial Carcinoma: Results from a Microarray Comparison. PLoS One. 2015; 10(8):e0137141.
  14. Meng MV. Editorial Comment. J Urol. 2015 Aug; 194(2):309.
  15. Meng M. Editorial comment for Sharma et al. J Endourol. 2015 May; 29(5):567-8.
  16. Rabow MW, Benner C, Shepard N, Meng MV. Concurrent urologic and palliative care after cystectomy for treatment of muscle-invasive bladder cancer. Urol Oncol. 2015 Jun; 33(6):267.e23-9.
  17. Tran G, Ramaswamy K, Chi T, Meng M, Freise C, Stoller ML. Laparoscopic Nephrectomy with Autotransplantation: Safety, Efficacy and Long-Term Durability. J Urol. 2015 Sep; 194(3):738-743.
  18. Meng MV. Editorial comment for Zargar et al. J Endourol. 2015 Jan; 29(1):102.
  19. Welty CJ, Cowan JE, Nguyen H, Shinohara K, Perez N, Greene KL, Chan JM, Meng MV, Simko JP, Cooperberg MR, Carroll PR. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. J Urol. 2015 Mar; 193(3):807-11.
  20. Meng MV, Boughey JC. Treating metastatic prostate cancer now and in the future. Bull Am Coll Surg. 2014 Sep; 99(9):55-7.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.